Mainz Biomed B.V. (MYNZ)
USD 3.36
(4.35%)
USD 3.36
(4.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 349.85 Thousand USD | 102.51% |
| 2022 | -13.91 Million USD | -126.19% |
| 2021 | -6.15 Million USD | -315.31% |
| 2020 | 2.85 Million USD | 29.26% |
| 2019 | 2.21 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 349.85 Thousand USD | -58.1% |
| 2023 Q2 | -2.37 Million USD | 66.75% |
| 2023 Q1 | -7.15 Million USD | 48.59% |
| 2023 Q3 | 835.07 Thousand USD | 135.11% |
| 2023 FY | 349.85 Thousand USD | 102.51% |
| 2022 Q2 | -23.51 Million USD | 0.0% |
| 2022 Q4 | -13.91 Million USD | 0.0% |
| 2022 FY | -13.91 Million USD | -126.19% |
| 2021 Q1 | -1.64 Million USD | -157.7% |
| 2021 FY | -6.15 Million USD | -315.31% |
| 2021 Q3 | -1.64 Million USD | -165.75% |
| 2021 Q4 | -6.15 Million USD | -273.14% |
| 2021 Q2 | 2.5 Million USD | 252.09% |
| 2020 FY | 2.85 Million USD | 29.26% |
| 2020 Q4 | 2.85 Million USD | 383.84% |
| 2020 Q3 | 590.47 Thousand USD | 0.0% |
| 2020 Q2 | 590.47 Thousand USD | 0.0% |
| 2020 Q1 | 590.47 Thousand USD | 34.31% |
| 2019 FY | 2.21 Million USD | 0.0% |
| 2019 Q4 | 439.61 Thousand USD | 0.0% |
| 2019 Q1 | 439.61 Thousand USD | 0.0% |
| 2019 Q2 | 439.61 Thousand USD | 0.0% |
| 2019 Q3 | 439.61 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 100.887% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 105.916% |
| Aspira Women's Health Inc. | -331 Thousand USD | 205.696% |
| Biodesix, Inc. | 34.3 Million USD | 98.98% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 106.036% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 128.148% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 128.148% |
| Bionano Genomics, Inc. | 34.88 Million USD | 98.997% |
| CareDx, Inc | -47.97 Million USD | 100.729% |
| Check-Cap Ltd. | -24.75 Million USD | 101.413% |
| Castle Biosciences, Inc. | -83.53 Million USD | 100.419% |
| DarioHealth Corp. | -7.54 Million USD | 104.635% |
| Exact Sciences Corporation | 1.94 Billion USD | 99.982% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 100.424% |
| Guardant Health, Inc. | 220.22 Million USD | 99.841% |
| ICON Public Limited Company | 3.56 Billion USD | 99.99% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 99.929% |
| Illumina, Inc. | 1.21 Billion USD | 99.971% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 106.44% |
| iSpecimen Inc. | -2.14 Million USD | 116.292% |
| Standard BioTools Inc. | 46.5 Million USD | 99.248% |
| MDxHealth SA | 18.88 Million USD | 98.147% |
| 23andMe Holding Co. | -141.37 Million USD | 100.247% |
| Medpace Holdings, Inc. | -103.32 Million USD | 100.339% |
| Myriad Genetics, Inc. | 88.1 Million USD | 99.603% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 114.341% |
| NeoGenomics, Inc. | 269.19 Million USD | 99.87% |
| Neogen Corporation | 735.62 Million USD | 99.952% |
| Inotiv, Inc. | 382.14 Million USD | 99.908% |
| Natera, Inc. | -200.1 Million USD | 100.175% |
| OpGen, Inc. | 11.89 Million USD | 97.058% |
| OPKO Health, Inc. | 230.68 Million USD | 99.848% |
| Psychemedics Corporation | 334 Thousand USD | -4.747% |
| Prenetics Global Limited | -43.33 Million USD | 100.807% |
| Prenetics Global Limited | -43.33 Million USD | 100.807% |
| Precipio, Inc. | -386 Thousand USD | 190.636% |
| Personalis, Inc. | -8.02 Million USD | 104.361% |
| RadNet, Inc. | 1.14 Billion USD | 99.97% |
| Sera Prognostics, Inc. | -2.02 Million USD | 117.302% |
| Sotera Health Company | 2.02 Billion USD | 99.983% |
| Neuronetics, Inc. | 2.79 Million USD | 87.492% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 102.281% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 102.281% |
| Trinity Biotech plc | 63.73 Million USD | 99.451% |
| T2 Biosystems, Inc. | 33.8 Million USD | 98.965% |
| Twist Bioscience Corporation | -192.4 Million USD | 100.182% |
| Exagen Inc. | -12.77 Million USD | 102.739% |